IceCure Medical Ltd.

IceCure Medical Ltd. has announced its Annual and Special General Meeting of Shareholders, scheduled for November 2, 2026. The meeting will be conducted via remote communication. Key agenda items include the re-appointment of the independent auditor, the re-appointment of a Class I director, and the approval of equity-based compensation grants for the CEO and Chairman. Shareholders of record as of October 1, 2026, are eligible to vote. The Board of Directors recommends a 'FOR' vote on all resolutions, excluding the discussion of the 2025 financial statements.

IceCure Medical reported a 45% year-over-year revenue increase to $1.8 million for the first half of 2026, driven by growth in both systems and disposable probes. Despite the revenue growth, the company posted a net loss of $8.775 million and ended the period with $12.0 million in cash and cash equivalents, bolstered by $8.5 million in gross proceeds from recent financings. The company acknowledged substantial doubts about its ability to continue as a going concern and is currently in mediation for a class action lawsuit seeking approximately $133.6 million in damages.

IceCure Medical Ltd. filed a Form 6-K disclosing the professional background of Mr. David Salton, a related party. The filing details his current role as Chief Executive Officer of AnchorMesh Ltd. since July 2024, and his previous positions including CEO of Virility Medical Ltd. and independent director roles at SHL Telemedicine Ltd., ARAN Research & Development (1982) Ltd., and InterCure Inc. This report is incorporated by reference into several of the company's registration statements.

IceCure Medical Ltd. announced a Special General Meeting of Shareholders on August 6, 2026, to approve amendments to its Series B and Series C warrants. The proposed changes include reducing the exercise price from $16.50 to $3.00 per share and extending the exercise periods for both warrant series. These amendments are part of an agreement with an investor and require shareholder approval.

IceCure Medical Ltd. is facing a class action lawsuit in Israel after the Tel Aviv District Court approved a motion to certify a class action and plaintiff classes on May 5, 2026. The lawsuit, originally filed in July 2021, alleges that a private placement conducted in March 2021 was at a significant discount and involved defects in its approval process. The company maintains that the claims are without merit and plans to file a motion for reconsideration by July 5, 2026, while also seeking a stay of proceedings for mediation.

IceCure Medical Ltd. announced it has regained compliance with the Nasdaq minimum bid price requirement. The company received written notice from Nasdaq on June 18, 2026, confirming it met the Nasdaq Listing Rule 5550(a)(2) by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days from June 4 to June 17, 2026. As a result, Nasdaq considers the bid price deficiency matter closed.

IceCure Medical Ltd. announced a private placement offering to an institutional investor, expecting to raise approximately $5.5 million in gross proceeds. The offering includes pre-funded warrants and Series D and E warrants to purchase 1,833,334 ordinary shares each, priced at $2.9999 per pre-funded warrant and accompanying warrants. The company also agreed to amend existing Series B and C warrants, reducing their exercise price from $16.50 to $3.00 per share, subject to shareholder approval. Separately, the company reported a 70% growth in its U.S. active commercial install base for breast cancer cryoablation following FDA clearance.

IceCure Medical Ltd. announced a 1-for-30 reverse share split to regain compliance with the Nasdaq $1.00 minimum bid price requirement and support its broader capital markets strategy. The split, approved by shareholders and the board, will reduce the number of outstanding shares from approximately 84.2 million to 2.8 million. Trading on a split-adjusted basis is set to begin on June 4, 2026, as the company proactively addresses regulatory requirements to maintain its Nasdaq listing.

IceCure Medical announced strong clinical data for its ProSense® cryoablation technology, presented at ECIO 2026. The ICESECRET trial showed an 89.4% recurrence-free rate for kidney cancer tumors 3 cm, with 83.9% recurrence-free at a median 4.0 years. Additionally, independent studies reported no residual early-stage breast cancer at 6 and 12 months with 100% excellent cosmetic outcomes, and a 92.9% fibroadenoma volume reduction at 12 months post-treatment. The company noted growing global momentum and interest in breast cryoablation, with a dedicated course at ECIO being overbooked.

IceCure Medical Ltd. announced it has been granted an additional 180-day extension by Nasdaq to regain compliance with the minimum $1.00 bid price requirement. The new deadline for the company to meet the rule is November 9, 2026. This extension follows an initial notification in November 2025, and IceCure Medical plans to cure the deficiency, potentially through a reverse share split, with no immediate impact on its Nasdaq listing.